View in EDS

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.

Saved in:
Bibliographic Details
Title: Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
Authors: Herman GA; Regeneron Pharmaceuticals, Tarrytown, NY, USA. Electronic address: gary.herman@regeneron.com., O'Brien MP; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Forleo-Neto E; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Sarkar N; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Isa F; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Hou P; Formerly of Regeneron Pharmaceuticals, Tarrytown, NY, USA., Chan KC; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Bar KJ; Department of Medicine and Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA., Barnabas RV; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Division of Allergy and Infectious Diseases and Department of Epidemiology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Cohen MS; Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Hurt CB; Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Burwen DR; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Marovich MA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Musser BJ; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Davis JD; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Turner KC; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Mahmood A; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Hooper AT; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Hamilton JD; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Parrino J; Formerly of Regeneron Pharmaceuticals, Tarrytown, NY, USA., Subramaniam D; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Baum A; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Kyratsous CA; Regeneron Pharmaceuticals, Tarrytown, NY, USA., DiCioccio AT; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Stahl N; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Braunstein N; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Yancopoulos GD; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Weinreich DM; Regeneron Pharmaceuticals, Tarrytown, NY, USA.
Corporate Authors: COVID-19 Phase 3 Prevention Trial Team
Source: The Lancet. Infectious diseases [Lancet Infect Dis] 2022 Oct; Vol. 22 (10), pp. 1444-1454. Date of Electronic Publication: 2022 Jul 05.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
Journal Info: Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35803290
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Herman+GA%22">Herman GA</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA. Electronic address: gary.herman@regeneron.com.<br /><searchLink fieldCode="AU" term="%22O'Brien+MP%22">O'Brien MP</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Forleo-Neto+E%22">Forleo-Neto E</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Sarkar+N%22">Sarkar N</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Isa+F%22">Isa F</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Hou+P%22">Hou P</searchLink>; Formerly of Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Chan+KC%22">Chan KC</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Bar+KJ%22">Bar KJ</searchLink>; Department of Medicine and Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Barnabas+RV%22">Barnabas RV</searchLink>; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA; Division of Allergy and Infectious Diseases and Department of Epidemiology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Barouch+DH%22">Barouch DH</searchLink>; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Cohen+MS%22">Cohen MS</searchLink>; Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Hurt+CB%22">Hurt CB</searchLink>; Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Burwen+DR%22">Burwen DR</searchLink>; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Marovich+MA%22">Marovich MA</searchLink>; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Musser+BJ%22">Musser BJ</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Davis+JD%22">Davis JD</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Turner+KC%22">Turner KC</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Mahmood+A%22">Mahmood A</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Hooper+AT%22">Hooper AT</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Hamilton+JD%22">Hamilton JD</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Parrino+J%22">Parrino J</searchLink>; Formerly of Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Subramaniam+D%22">Subramaniam D</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Baum+A%22">Baum A</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Kyratsous+CA%22">Kyratsous CA</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22DiCioccio+AT%22">DiCioccio AT</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Stahl+N%22">Stahl N</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Braunstein+N%22">Braunstein N</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Yancopoulos+GD%22">Yancopoulos GD</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Weinreich+DM%22">Weinreich DM</searchLink>; Regeneron Pharmaceuticals, Tarrytown, NY, USA.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22COVID-19+Phase+3+Prevention+Trial+Team%22">COVID-19 Phase 3 Prevention Trial Team</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101130150%22">The Lancet. Infectious diseases</searchLink> [Lancet Infect Dis] 2022 Oct; Vol. 22 (10), pp. 1444-1454. <i>Date of Electronic Publication: </i>2022 Jul 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101130150 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-4457 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214733099%22">14733099 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Infect Dis <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35803290
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1473-3099(22)00416-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1444
    Titles:
      – TitleFull: Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Herman GA
      – PersonEntity:
          Name:
            NameFull: O'Brien MP
      – PersonEntity:
          Name:
            NameFull: Forleo-Neto E
      – PersonEntity:
          Name:
            NameFull: Sarkar N
      – PersonEntity:
          Name:
            NameFull: Isa F
      – PersonEntity:
          Name:
            NameFull: Hou P
      – PersonEntity:
          Name:
            NameFull: Chan KC
      – PersonEntity:
          Name:
            NameFull: Bar KJ
      – PersonEntity:
          Name:
            NameFull: Barnabas RV
      – PersonEntity:
          Name:
            NameFull: Barouch DH
      – PersonEntity:
          Name:
            NameFull: Cohen MS
      – PersonEntity:
          Name:
            NameFull: Hurt CB
      – PersonEntity:
          Name:
            NameFull: Burwen DR
      – PersonEntity:
          Name:
            NameFull: Marovich MA
      – PersonEntity:
          Name:
            NameFull: Musser BJ
      – PersonEntity:
          Name:
            NameFull: Davis JD
      – PersonEntity:
          Name:
            NameFull: Turner KC
      – PersonEntity:
          Name:
            NameFull: Mahmood A
      – PersonEntity:
          Name:
            NameFull: Hooper AT
      – PersonEntity:
          Name:
            NameFull: Hamilton JD
      – PersonEntity:
          Name:
            NameFull: Parrino J
      – PersonEntity:
          Name:
            NameFull: Subramaniam D
      – PersonEntity:
          Name:
            NameFull: Baum A
      – PersonEntity:
          Name:
            NameFull: Kyratsous CA
      – PersonEntity:
          Name:
            NameFull: DiCioccio AT
      – PersonEntity:
          Name:
            NameFull: Stahl N
      – PersonEntity:
          Name:
            NameFull: Braunstein N
      – PersonEntity:
          Name:
            NameFull: Yancopoulos GD
      – PersonEntity:
          Name:
            NameFull: Weinreich DM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2022 Oct
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1474-4457
          Numbering:
            – Type: volume
              Value: 22
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: The Lancet. Infectious diseases
              Type: main
ResultId 1